In this year’s Semper Maior report, in addition to the usual analysis of how Core Biotech performed, we’ll review the biotech M&A landscape over the past several years, best practices for preparing for M&A, and tips for executing on a deal if and when the time comes. We’ll examine the crucial roles various advisors may play along the way. We’ll take stock of who’s buying, what they’re buying, and why. We’ll share some advice we’ve gleaned from some of the smartest and most connected dealmakers in biotech. A small mistake can be worth an astounding amount considering the many years of value creation that leads up to an exit.

The many fees and expenses associated with running any company are more than just a headache. Particularly for R&D-intensive biotech companies, failing to stay on top of them can significantly saddle a company with unnecessary cash burn. A new video resource at RA Capital's free Gateway platform for boards and biotech leadership features industry leaders sharing their experiences navigating these pesky financial challenges.

The federal government must address the failure of Silicon Valley Bank (SVB) with speed and clarity before it metastasizes into a national crisis, so the ecosystem of institutions in which SVB has operated, including other banks and investors, can help bridge companies so that they can continue to operate while they wait for their deposits.

The run-on-the-bank panic around SVB would have been quelled if everyone was dissuaded from succumbing to mass hysteria. Understanding what happened can help prevent further bank runs.